Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis

• Published in: Journal of the American Heart Association 2021-10, Vol.10 (20), p.e022575-e022575
• Main Authors: Uchiyama, Shinichiro, Toyoda, Kazunori, Omae, Katsuhiro, Saita, Ryotaro, Kimura, Kazumi, Hoshino, Haruhiko, Sakai, Nobuyuki, Okada, Yasushi, Tanaka, Kortaro, Origasa, Hideki, Naritomi, Hiroaki, Houkin, Kiyohiro, Yamaguchi, Keiji, Isobe, Masanori, Minematsu, Kazuo, Matsumoto, Masayasu, Tominaga, Teiji, Tomimoto, Hidekazu, Terayama, Yasuo, Yasuda, Satoshi, Yamaguchi, Takenori
• Format: Article
• Language: English
• Subjects: Cilostazol - adverse effects; Drug Therapy, Combination - adverse effects; Humans; Intracranial Arteriosclerosis - drug therapy; Original Research; Platelet Aggregation Inhibitors - adverse effects; Stroke - drug therapy; Treatment Outcome
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.121.022575

Background Long-term benefit of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) for the prevention of recurrent stroke has not been established in patients with intracranial arterial stenosis. We compared the efficacy and safety of DAPT with cilostazol and clopidogrel or aspirin to those of SAPT with clopidogrel or aspirin in patients with intracranial arterial stenosis, who were recruited to the Cilostazol Stroke Prevention Study for Antiplatelet Combination trial, a randomized controlled trial in high-risk Japanese patients with ischemic stroke. Methods and Results We compared the vascular and hemorrhagic events between DAPT and SAPT in patients with ischemic stroke and symptomatic or asymptomatic intracranial arterial stenosis of at least 50% in a major intracranial artery. Patients were placed in two groups: 275 were assigned to receive DAPT and 272 patients SAPT. The risks of ischemic stroke (hazard ratio [HR], 0.47; 95% CI, 0.23-0.95); and composite of stroke, myocardial infarction, and vascular death (HR, 0.48; 95% CI, 0.26-0.91) were lower in DAPT than SAPT, whereas the risk of severe or life-threatening bleeding (HR, 0.72; 95% CI, 0.12-4.30) did not differ between the 2 treatment groups. Conclusions DAPT using cilostazol was superior to SAPT with clopidogrel or aspirin for the prevention of recurrent stroke and vascular events without increasing bleeding risk among patients with intracranial arterial stenosis after stroke. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01995370.